Clinicopathological characteristics and prognosis of stage IV XXXX .

@entity1 @entity5 @entity14 @entity65 @entity1349
UNASSIGNED: The aim of this study was to determine the role of curative resection in metastatic @entity14 ( @entity14 ) and determine the subset of @entity1 who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 @entity1 diagnosed with synchronous liver and/or lung metastatic @entity14 at the Osaka Medical Center for @entity5 and @entity65 between 1983 and 2010 were retrospectively investigated. All the @entity1 underwent curative resection of the primary and metastatic lesions. The median follow-up time was 5.69 years. A total of 83 and 13 @entity1 had only liver or lung metastasis, respectively, whereas 7 @entity1 had synchronous liver and lung metastases. A total of 25 @entity1 (24.2%) had no recurrence following curative resection and 14 @entity1 (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter. The 5-year survival of liver or lung metastatic @entity14 was 43.7 or 90.0%, respectively. However, the median @entity1349 ( @entity1349 ) in @entity1 with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, @entity5 invasion, synchronous liver and lung metastases and time-to-recurrence after the first curative resection were significantly associated with @entity1349 and disease-free survival. In conclusion, curative resection confers longer-term survival in @entity1 with liver or lung metastatic @entity14 .
